Review Increasing Complexity of the Dystrophin-Associated Protein Complex Jonathon M

Total Page:16

File Type:pdf, Size:1020Kb

Review Increasing Complexity of the Dystrophin-Associated Protein Complex Jonathon M Proc. Nadl. Acad. Sci. USA Vol. 91, pp. 8307-8313, August 1994 Review Increasing complexity of the dystrophin-associated protein complex Jonathon M. Tinsley, Derek J. Blake, Richard A. Zuellig, and Kay E. Davies Molecular Genetics Group, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DU, United Kingdom ABSTRACT Duchenne muscular dys- Purkinje neurons. Alternatively spliced dystrophin-1 (Dp7l) and apo-dystro- trophy is a severe X chromosome-linked, isoforms originating from the carboxyl- phin-3 are regulated by a promoter situ- muscle-wasting disease caused by lack of terminal coding region ofdystrophin have ated between exons 62 and 63 of the the protein dystrophin. The exact function also been described. The significance of dystrophin gene and are expressed in of dystrophin rem to be determined. these isoforms at the RNA and protein nonmuscle tissues, including brain, lung, However, analysis of its interaction with a level has not been elucidated. liver, and kidney. Apo-dystrophin-1 tran- large oligomeric protein complex at the Dystrophin is a 427-kDa protein local- scripts are only detectable in fetal and sarcolemma and the identicaton of a ized to the cytoplasmic face of the sar- newborn muscle. Muscle samples taken structurally related protein, utrophin, is colemma, enriched at myotendinous after 15 days postnatally have no apo- leading to the characterization ofcandidate junctions and the postsynaptic mem- dystrophin-1 transcript as determined by genes for other neuromusular disorders. brane of the neuromuscular junction reverse transcription-PCR. In rat brain, (NMJ). Dystrophin colocalizes with apo-dystrophin-1 transcripts continue in- Duchenne muscular dystrophy (DMD) is f3-spectrin and vinculin in three distinct creasing until they reach a maximum the most common muscular dystrophy, domains at the sarcolemma (overlaying after -1 mo. Thus apo-dystrophin-1 ap- affecting 1 in 3,300 boys. It leads to both I bands and M lines), lying as an pears to be developmentally regulated in severe muscle wasting and eventual array ofthick bands localizing at the sites muscle and brain (4). Dpll6 (apo- death in the late teens or early twenties of attachment of the sarcomeres to the dystrophin-2) is regulated by a promoter due to cardiac or respiratory failure. muscle plasma membrane. The carboxyl- situated between exons 55 and 56 of the Becker muscular dystrophy (BMD) is an terminal region of dystrophin is bound to dystrophin gene and is expressed in pe- allelic disorder that is less common (1 in the protoplasmic half of the plasma- ripheral nerve. In contrast to dystrophin, 30,000 boys) and less severe, with a later lemma. Thus dystrophin forms an intri- neither apo-dystrophin-1 nor apo-dystro- onset and much longer survival rate. cate part of the muscle cytoskeleton and phin-2 is expressed before organogenesis Both disorders are caused by mutations may function to link the normal contrac- in the developing mouse embryo (5). within the dystrophin gene, resulting in a tile apparatus to the sarcolemma. In the Apo-dystrophin-1 is first detected at 11.5 lack of dystrophin (usually DMD) or the brain, dystrophin is also localized at the days in the ventral midline of the hind- expression ofmutant forms ofdystrophin postsynaptic regions of some neurons. brain. Later expression of apo-dystro- (usually BMD). Dystrophin is a member The amino terminus of dystrophin has phin-1 occurs in central nervous system of a growing family of related proteins, been shown in vitro to contain a functional glia, teeth primordia, and in the liver. including the autosomally encoded pro- actin-binding domain. Deletions within Apo-dystrophin-2 appears to be a rare tein utrophin. There have been several this region ofthe dystrophin gene result in transcript during development but is de- recent reviews covering the structure and a range of phenotypes from mild to se- tected at low levels in the region of the potential functions of dystrophin and vere, suggesting that the ability to bind caudate putamen in newborn mouse utrophin, and the reader is referred to actin is an important, but not an absolute, brain (5). these for detailed references (1-3). This requirement for dystrophin function. The Utrophin is a 395-kDa protein encoded review focuses on the proteins with central rod domain consists ofa numberof by a large (1 Mb) multi-exonic gene lo- which dystrophin and utrophin interact. a-helical coiled-coil repeats that are sim- cated on chromosome 6q24(6). The amino ilar to spectrin and probably give the acid sequence shows that utrophin has a Dystrphin and Utrophin Genes: molecule a flexible rod-shaped structure. strong similarity to dystrophin. Utrophin A Brief Overview In-frame deletions within this domain usu- has an amino-terminal actin-binding do- ally give rise to intermediate or milder main (S. J. Winder, L. Hemmings, S. K. The dystrophin gene is the largest gene so BMD. The carboxyl-terminal domain has Maciver, S. J. Bolton, J.M.T., K.E.D., far identified in humans, covering >2.5 no homology with any other identified D. R. Critchley, and J. Kendrick-Jones, megabases and containing 79 exons. The sequences apart from the related protein personal communication), a repeated unusually high mutation rate at the DMD utrophin. Mutations in the cysteine-rich coiled-coil rod domain, and a cysteine- locus may, inpart, be accountedforby the domain and first half of the carboxyl- rich carboxyl-terminal domain. In normal large size of the gene. The corresponding terminal domain almost always result in adult muscle, utrophin is localized at the 14-kb dystrophin mRNA is expressed pre- severe DMD phenotypes, indicating their membrane of the NMJ. High-resolution dominantly in skeletal, cardiac, and importance for the normal function of analysis of rat NMJs suggests that utro- smooth muscle; lower levels appear in dystrophin. Loss of the last 200 amino phin is colocalized with the acetylcholine brain. Transcription of dystrophin in dif- acids ofdystrophin appears to produce an receptors (AChRs) at the crests of the ferent tissues is regulated from either the intermediate DMD/BMDphenotype. The junctional folds (7) and may play a role in brain promoter (predominantly active in potential functions of the dystrophin car- neuronal cells) or muscle promoter (dif- boxyl terminus are discussed later. Abbreviations: DMD, Duchenne muscular ferentiated myogenic cells and primary Three shorter transcripts, expressed dystrophy; BMD, Becker muscular dystro- glial cells) giving rise to different first from two different phy; NMJ, neuromuscular junction; DAP, promoters, encode dystrophin-associated protein; DAG, dystro- exons. A thirdpromoterbetweenthe mus- proteins that have a majority ofsequence phin-associated glycoprotein; AChR, acetyl- cle promoter and the second exon ofdys- identical to that of the cysteine-rich and choline receptor; SCARMD, severe childhood trophin regulates expression in cerebellar carboxyl terminus of dystrophin. Apo- autosomal-recessive muscular dystrophy. 8307 Downloaded by guest on September 28, 2021 8308 Review: Tinsley et al. Proc. Natl. Acad. Sci. USA 91 (1994) the clustering of AChRs (8). In fetal mus- complex and other associated proteins cle (18). The protein consists of a short cle development, utrophin is expressed localized to the sarcolemma (described signal sequence, one transmembrane do- before dystrophin. Higher levels of utro- later). main, and two potential sites for N-linked phin mRNA have been detected in human The 43DAG (A3) and 156DAG are de- glycosylation. In contrast to dystrogly- and mouse fetal tissue compared with rived from a single 97-kDa precursor pro- can, expression of the SODAG is specific adult. In normal humanfetal muscle, utro- tein translated from a 3.8-kb transcript to skeletal, cardiac, and smooth muscle phin is localized to the sarcolemma and (15). The 43-156DAG transcript is ex- (18, 19). This protein has been renamed NMJs, showing maximum expression at pressed not only in skeletal, cardiac, and adhalin (from the Arabic word for mus- 17-18 weeks of gestation (9). When dys- smooth muscle but also in other tissues- cle, adhal). trophin is expressed, utrophin is gradually namely, brain, lung, liver, and kidney. At present the cloning of the 35DAG depleted from the sarcolemma to be re- Cleavage and posttranslational modifica- (A4) and 25DAP (AS) has not been re- placed by dystrophin, leaving the NMJs tion of the carboxyl-terminal portion ported, so their potential functions have as the only site ofutrophinlocalization (9). gives rise to the 43DAG. The 43DAG has yet to be elucidated. However, 35DAG It is not known whether utrophin has a sites for glycosylation, a transmembrane expression appears restricted to striated functional role while located at the fetal domain, and a cytoplasmic tail (15). On muscle (19). A 94-kDa protein, AO, which sarcolemma-i.e., the fetal form of dys- acrylamide gels, the 43DAG (A3) is a also copurifies with the DAP complex, trophin-or is simply in the process of component of a doublet, A3a and A3b has been identified (12). Circumstantial iigrating with the developing AChR clus- (12, 16). The 43DAG is the same as A3a, evidence suggests that AO may be related ters beforeformation ofthe mature NMJs. as determined by peptide sequence anal- to the Torpedo 87-kDa postsynaptic pro- In contrast to dystrophin, utrophin is de- ysis of the purified gel band. A3b is tein (discussed later). tectable in most tissues-particularly the distinct from A3a, as it has a different Recently, the purified DAP complex lung, blood vessels, and nerves. Utrophin proteolytic cleavage pattern (14) and is purified from rabbit skeletal muscle has is enriched in the vascular regions of the unable to bind dystrophin (16). The 56- been divided into three subcomplexes brain-for instance, the choroid plexus kDa amino-terminal core protein once based upon detergent solubilization using and at the astrocytic foot processes ofthe glycosylated at many of the potential 1-octyl f-D-glucoside (14).
Recommended publications
  • Large-Scale Opening of Utrophints Tandem Calponin Homology (CH
    Large-scale opening of utrophin’s tandem calponin homology (CH) domains upon actin binding by an induced-fit mechanism Ava Y. Lin, Ewa Prochniewicz, Zachary M. James, Bengt Svensson, and David D. Thomas1 Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455 Edited by James A. Spudich, Stanford University School of Medicine, Stanford, CA, and approved June 20, 2011 (received for review April 21, 2011) We have used site-directed spin labeling and pulsed electron has prevented the development of a reliable structural model for paramagnetic resonance to resolve a controversy concerning the any of these complexes. A major unresolved question concerns structure of the utrophin–actin complex, with implications for the the relative disposition of the tandem CH domains (CH1 and pathophysiology of muscular dystrophy. Utrophin is a homolog of CH2) (9, 10). Crystal structures of the tandem CH domains dystrophin, the defective protein in Duchenne and Becker muscular showed a closed conformation for fimbrin (11) and α-actinin (12), dystrophies, and therapeutic utrophin derivatives are currently but an open conformation for both utrophin (Utr261) (Fig. 1A) being developed. Both proteins have a pair of N-terminal calponin and dystrophin (Dys246) (16). The crystal structure of Utr261 homology (CH) domains that are important for actin binding. suggests that the central helical region connecting CH1 and CH2 Although there is a crystal structure of the utrophin actin-binding is highly flexible. Even for α-actinin, which has a closed crystal domain, electron microscopy of the actin-bound complexes has structure, computational analysis suggests the potential for a high produced two very different structural models, in which the CH do- degree of dynamic flexibility that facilitates actin binding (17).
    [Show full text]
  • Multiomic Approaches to Uncover the Complexities of Dystrophin-Associated Cardiomyopathy
    International Journal of Molecular Sciences Review Multiomic Approaches to Uncover the Complexities of Dystrophin-Associated Cardiomyopathy Aoife Gowran 1,*, Maura Brioschi 2, Davide Rovina 1 , Mattia Chiesa 3,4 , Luca Piacentini 3,* , Sara Mallia 1, Cristina Banfi 2,* , Giulio Pompilio 1,5,6,* and Rosaria Santoro 1,4 1 Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, 20138 Milan, Italy; [email protected] (D.R.); [email protected] (S.M.); [email protected] (R.S.) 2 Unit of Cardiovascular Proteomics, Centro Cardiologico Monzino-IRCCS, 20138 Milan, Italy; [email protected] 3 Bioinformatics and Artificial Intelligence Facility, Centro Cardiologico Monzino-IRCCS, 20138 Milan, Italy; [email protected] 4 Department of Electronics, Information and Biomedical Engineering, Politecnico di Milano, 20133 Milan, Italy 5 Department of Cardiac Surgery, Centro Cardiologico Monzino-IRCCS, 20138 Milan, Italy 6 Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy * Correspondence: [email protected] (A.G.); [email protected] (L.P.); cristina.banfi@cardiologicomonzino.it (C.B.); [email protected] (G.P.) Abstract: Despite major progress in treating skeletal muscle disease associated with dystrophinopathies, cardiomyopathy is emerging as a major cause of death in people carrying dystrophin gene mutations that remain without a targeted cure even with new treatment directions and advances in modelling Citation: Gowran, A.; Brioschi, M.; abilities. The reasons for the stunted progress in ameliorating dystrophin-associated cardiomyopathy Rovina, D.; Chiesa, M.; Piacentini, L.; (DAC) can be explained by the difficulties in detecting pathophysiological mechanisms which can also Mallia, S.; Banfi, C.; Pompilio, G.; Santoro, R.
    [Show full text]
  • Molecular Genetic Analysis of the Adenomatous Polyposis Coli (APC)
    Molecular Genetic Analysis of the Adenomatous Polyposis Coli(APC) gene region by Garret Malcolm Hampton A thesis submitted in requirement for the degree of Doctor of Philosophy at the University of London May, 1992 Cancer Genetics Laboratory (formerly Director's Laboratory) Imperial Cancer Research Fund London and Department of Genetics and Biometry University College London London University Page -1- ProQuest Number: 10609182 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10609182 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 To my parents and my wife, Kate Page -2- Abstract Familial Adenomatous Polyposis (FAP) is a rare, autosomal dominant predisposition to colorectal cancer, affecting about one in ten thousand individuals in all populations studied. The gene responsible for this syndrome, designated APC (for Adenomatous Polyposis Coli) was mapped to 5q21-q22 by linkage analysis following a cytogenetic report of a male patient with polyposis and an interstitial deletion on 5q. The high incidence of allele loss at 5q21-q22 in carcinomas of sporadic patients suggests that mutation of the APC gene is a very frequent step in the tumorigenic pathway to nonfamilial colorectal carcinomas and emphasises the importance of isolating the gene and identifying its function.
    [Show full text]
  • Reevaluating αE-Catenin Monomer and Homodimer Functions By
    Saint Mary's College of California Saint Mary's Digital Commons Scholarship, Research, Creative Activities, and School of Science Faculty Works Community Engagement 9-28-2015 Reevaluating αE-catenin monomer and homodimer functions by characterizing E-cadherin/αE-catenin chimeras Julie M. Bianchini Stanford University Khameeka N. Kitt Stanford University, [email protected] Martijn Gloerich Stanford University Sabine Pokutta Stanford University William I. Weis Stanford University Follow this and additional works at: https://digitalcommons.stmarys-ca.edu/school-science-faculty-works Part of the Biology Commons Repository Citation Bianchini, Julie M.; Kitt, Khameeka N.; Gloerich, Martijn; Pokutta, Sabine; and Weis, William I.. Reevaluating αE-catenin monomer and homodimer functions by characterizing E-cadherin/αE-catenin chimeras (2015). Journal of Cellular Biology. 210 (7), 1065-1074. 10.1083/jcb.201411080 [article]. https://digitalcommons.stmarys-ca.edu/school-science-faculty-works/950 This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License. This Article is brought to you for free and open access by the Scholarship, Research, Creative Activities, and Community Engagement at Saint Mary's Digital Commons. It has been accepted for inclusion in School of Science Faculty Works by an authorized administrator of Saint Mary's Digital Commons. For more information, please contact [email protected]. JCB: Report Reevaluating αE-catenin monomer and homodimer functions by characterizing E-cadherin/αE-catenin chimeras Julie M. Bianchini,1 Khameeka N. Kitt,1 Martijn Gloerich,1 Sabine Pokutta,2 William I. Weis,2,3 and W. James Nelson1,3 1Department of Biology, 2Department of Structural Biology, and 3Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305 As part of the E-cadherin–β-catenin–αE-catenin complex (CCC), mammalian αE-catenin binds F-actin weakly in the absence of force, whereas cytosolic αE-catenin forms a homodimer that interacts more strongly with F-actin.
    [Show full text]
  • Dystrophin Complex Functions As a Scaffold for Signalling Proteins☆
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1838 (2014) 635–642 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbamem Review Dystrophin complex functions as a scaffold for signalling proteins☆ Bruno Constantin IPBC, CNRS/Université de Poitiers, FRE 3511, 1 rue Georges Bonnet, PBS, 86022 Poitiers, France article info abstract Article history: Dystrophin is a 427 kDa sub-membrane cytoskeletal protein, associated with the inner surface membrane and Received 27 May 2013 incorporated in a large macromolecular complex of proteins, the dystrophin-associated protein complex Received in revised form 22 August 2013 (DAPC). In addition to dystrophin the DAPC is composed of dystroglycans, sarcoglycans, sarcospan, dystrobrevins Accepted 28 August 2013 and syntrophin. This complex is thought to play a structural role in ensuring membrane stability and force trans- Available online 7 September 2013 duction during muscle contraction. The multiple binding sites and domains present in the DAPC confer the scaf- fold of various signalling and channel proteins, which may implicate the DAPC in regulation of signalling Keywords: Dystrophin-associated protein complex (DAPC) processes. The DAPC is thought for instance to anchor a variety of signalling molecules near their sites of action. syntrophin The dystroglycan complex may participate in the transduction of extracellular-mediated signals to the muscle Sodium channel cytoskeleton, and β-dystroglycan was shown to be involved in MAPK and Rac1 small GTPase signalling. More TRPC channel generally, dystroglycan is view as a cell surface receptor for extracellular matrix proteins.
    [Show full text]
  • Gene Therapy Rescues Cardiac Dysfunction in Duchenne Muscular
    JACC: BASIC TO TRANSLATIONAL SCIENCE VOL.4,NO.7,2019 ª 2019 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd/4.0/). PRECLINICAL RESEARCH Gene Therapy Rescues Cardiac DysfunctioninDuchenneMuscular Dystrophy Mice by Elevating Cardiomyocyte Deoxy-Adenosine Triphosphate a b c d,e Stephen C. Kolwicz, JR,PHD, John K. Hall, PHD, Farid Moussavi-Harami, MD, Xiolan Chen, PHD, d,e b,d,e e,f,g, b,e,g, Stephen D. Hauschka, PHD, Jeffrey S. Chamberlain, PHD, Michael Regnier, PHD, * Guy L. Odom, PHD * VISUAL ABSTRACT Kolwicz, S.C. Jr. et al. J Am Coll Cardiol Basic Trans Science. 2019;4(7):778–91. HIGHLIGHTS rAAV vectors increase cardiac-specific expression of RNR and elevate cardiomyocyte 2-dATP levels. Elevated myocardial RNR and subsequent increase in 2-dATP rescues the performance of failing myocardium, an effect that persists long term. ISSN 2452-302X https://doi.org/10.1016/j.jacbts.2019.06.006 JACC: BASIC TO TRANSLATIONAL SCIENCE VOL. 4, NO. 7, 2019 Kolwicz, Jr., et al. 779 NOVEMBER 2019:778– 91 Nucleotide-Based Cardiac Gene Therapy Restores Function in dmd Mice We show the ability to increase both cardiac baseline function and high workload contractile performance in ABBREVIATIONS aged (22- to 24-month old) mdx4cv mice, by high-level muscle-specific expression of either microdystrophin AND ACRONYMS or RNR. mDys = microdystrophin Five months post-treatment, mice systemically injected with rAAV6 vector carrying a striated muscle-specific CK8 regulatory cassette driving expression of microdystrophin in both skeletal and cardiac muscle, exhibited the = miniaturized murine creatine kinase regulatory greatest effect on systolic function.
    [Show full text]
  • Snapshot: Actin Regulators II Anosha D
    SnapShot: Actin Regulators II Anosha D. Siripala and Matthew D. Welch Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA Representative Proteins Protein Family H. sapiens D. melanogaster C. elegans A. thaliana S. cerevisiae Endocytosis and Exocytosis ABP1/drebrin mABP1, drebrin, drebrin- †Q95RN0 †Q9XUT0 Abp1 like EPS15 EPS15 Eps-15 EHS-1 †Q56WL2 Pan1 HIP1R HIP1R †Q8MQK1 †O62142 Sla2 Synapsin synapsin Ia, Ib, IIa, IIb, III Synapsin SNN-1 Plasma Membrane Association Anillin anillin Scraps ANI-1, 2, 3 Annexins annexin A1–11, 13 (actin Annexin B9-11 NEX-1–4 ANN1-8 binding: 1, 2, 6) ERM proteins ezrin, radixin, moesin DMoesin ERM-1 MARCKS MARCKS, MRP/ Akap200 MACMARCKS/F52 Merlin *merlin/NF2 Merlin NFM-1 Protein 4.1 4.1R, G, N, B Coracle Spectrin α-spectrin (1–2), β-spectrin α-spectrin, β-spectrin, β heavy- SPC-1 (α-spectrin), UNC-70 (1–4), β heavy-spectrin/ spectrin/Karst (β-spectrin), SMA-1 (β heavy- karst spectrin) Identifi ed Cellular Role: X Membrane traffi cking and phagocytosis Cell-Cell Junctions X Cytokinesis α-catenin α-catenin 1–3 α-catenin HMP-1 X Cell surface organization and dynamics X Cell adhesion Afadin afadin/AF6 Canoe AFD-1 X Multiple functions ZO-1 ZO-1, ZO-2, ZO-3 ZO-1/Polychaetoid †Q56VX4 X Other/unknown Cell-Extracellular Matrix Junctions †UNIPROT database accession number *Mutation linked to human disease Dystrophin/utrophin *dystrophin, utrophin/ Dystrophin DYS-1 DRP1, DRP2 LASP LASP-1, LASP-2, LIM- Lasp †P34416 nebulette Palladin palladin Parvin α-, β-, χ-parvin †Q9VWD0 PAT-6
    [Show full text]
  • Impacts of Dystrophin and Utrophin Domains on Actin Structural Dynamics: Implications for Therapeutic Design
    doi:10.1016/j.jmb.2012.04.005 J. Mol. Biol. (2012) 420,87–98 Contents lists available at www.sciencedirect.com Journal of Molecular Biology journal homepage: http://ees.elsevier.com.jmb Impacts of Dystrophin and Utrophin Domains on Actin Structural Dynamics: Implications for Therapeutic Design Ava Yun Lin, Ewa Prochniewicz, Davin M. Henderson, Bin Li, James M. Ervasti and David D. Thomas⁎ Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, 6-155 Jackson Hall, 321 Church Street SE, Minneapolis, MN 55455, USA Received 27 January 2012; We have used time-resolved phosphorescence anisotropy (TPA) of actin received in revised form to evaluate domains of dystrophin and utrophin, with implications for 26 March 2012; gene therapy in muscular dystrophy. Dystrophin and its homolog accepted 2 April 2012 utrophin bind to cytoskeletal actin to form mechanical linkages that Available online prevent muscular damage. Because these proteins are too large for most 11 April 2012 gene therapy vectors, much effort is currently devoted to smaller constructs. We previously used TPA to show that both dystrophin and Edited by R. Craig utrophin have a paradoxical effect on actin rotational dynamics— restricting amplitude while increasing rate, thus increasing resilience, Keywords: with utrophin more effective than dystrophin. Here, we have evaluated time-resolved individual domains of these proteins. We found that a “mini-dystrophin,” phosphorescence anisotropy; lacking one of the two actin-binding domains, is less effective than TPA; dystrophin in regulating actin dynamics, correlating with its moderate muscular dystrophy; effectiveness in rescuing the dystrophic phenotype in mice. In contrast, gene therapy we found that a “micro-utrophin,” with more extensive internal deletions, is as effective as full-length dystrophin in the regulation of actin dynamics.
    [Show full text]
  • Muscle Disorders
    Brain Pathology 7: 1289-1291 (1997) KEYNOTE LECTURE KL5.1 - Muscle Disorders KL5.1 Molecular diagnosis of muscular dystrophies various tissues and identified as the 156kDaa-dystro- glycan and 43kDap-dystroglycan in skeletal muscle. Dr. Hideo Sugita a-dystroglycan , an extracellular protein, binds to one National Center of Neurology and Psychiatry, Kodaira Tokyo of the main components of the extracellular matrix, 187, Japan laminin probably through its sugar chains. a-dystroglycan binds to P-dystroglycan, a trans- The muscular dystrophies comprise clinically and membraneous pro1 ein. genetically heterogeneous group of disorders. Inside the mussle cell, a-dystroglycan binds to the Since the discovery of the gene and gene product of cysteine-rich domain and fxst half of the C-terminal Duchenne (DMD)/Becker muscular dystrophy (BMD), domain of dystrorhin. At the N--terminal regions, dys- dystrophin by Louis Kunkel's group in late 1980, enor- trophin molecule binds to actin-filament. mous progress has been achieved in understanding the There is a connecting axis anchored by laminin pathomechanism, as well as the diagnosis of between the subsarcolemmal cytoskeletons and extra- DMDBMD and related muscular dystrophies at the cellular matrix, which is called the "dystrophin-axis" ( molecular level. actin-dystrophin-dystroglycan complex). In addition to interest in dystrophin, defects of which This axis may play an important role to construct a give rise to DMDBMD, much interest of researchers in cell-matrix adhesion junction to fix the sarcolemma to muscular dystrophies has been concentrated to plasma the mechanically tough basal lamina, forming a protec- membrane and its associated architectures of muscle tion system to the sarcolemma during contraction and fibers.
    [Show full text]
  • N2A Titin: Signaling Hub and Mechanical Switch in Skeletal Muscle
    International Journal of Molecular Sciences Review N2A Titin: Signaling Hub and Mechanical Switch in Skeletal Muscle Kiisa Nishikawa 1,* , Stan L. Lindstedt 1, Anthony Hessel 2 and Dhruv Mishra 1 1 Department of Biological Sciences, Northern Arizona University, Flagstaff, AZ 86011-5640, USA; [email protected] (S.L.L.); [email protected] (D.M.) 2 Institute of Physiology II, University of Münster, 48149 Münster, Germany; [email protected] * Correspondence: [email protected]; Tel.: +1-928-523-9497 Received: 12 May 2020; Accepted: 1 June 2020; Published: 1 June 2020 Abstract: Since its belated discovery, our understanding of the giant protein titin has grown exponentially from its humble beginning as a sarcomeric scaffold to recent recognition of its critical mechanical and signaling functions in active muscle. One uniquely useful model to unravel titin’s functions, muscular dystrophy with myositis (mdm), arose spontaneously in mice as a transposon-like LINE repeat insertion that results in a small deletion in the N2A region of titin. This small deletion profoundly affects hypertrophic signaling and muscle mechanics, thereby providing insights into the function of this specific region and the consequences of its dysfunction. The impact of this mutation is profound, affecting diverse aspects of the phenotype including muscle mechanics, developmental hypertrophy, and thermoregulation. In this review, we explore accumulating evidence that points to the N2A region of titin as a dynamic “switch” that is critical for both mechanical and signaling functions in skeletal muscle. Calcium-dependent binding of N2A titin to actin filaments triggers a cascade of changes in titin that affect mechanical properties such as elastic energy storage and return, as well as hypertrophic signaling.
    [Show full text]
  • Diagnosis and Cell-Based Therapy for Duchenne Muscular Dystrophy in Humans, Mice, and Zebrafish
    J Hum Genet (2006) 51:397–406 DOI 10.1007/s10038-006-0374-9 MINIREVIEW Louis M. Kunkel Æ Estanislao Bachrach Richard R. Bennett Æ Jeffrey Guyon Æ Leta Steffen Diagnosis and cell-based therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish Received: 3 January 2006 / Accepted: 4 January 2006 / Published online: 1 April 2006 Ó The Japan Society of Human Genetics and Springer-Verlag 2006 Abstract The muscular dystrophies are a heterogeneous mutants carries a stop codon mutation in dystrophin, group of genetically caused muscle degenerative disor- and we have recently identified another carrying a ders. The Kunkel laboratory has had a longstanding mutation in titin. We are currently positionally cloning research program into the pathogenesis and treatment of the disease-causative mutation in the remaining 12 mu- these diseases. Starting with our identification of dys- tant strains. We hope that one of these new mutant trophin as the defective protein in Duchenne muscular strains of fish will have a mutation in a gene not previ- dystrophy (DMD), we have continued our work on ously implicated in human muscular dystrophy. This normal dystrophin function and how it is altered in gene would become a candidate gene to be analyzed in muscular dystrophy. Our work has led to the identifi- patients which do not carry a mutation in any of the cation of the defective genes in three forms of limb girdle known dystrophy-associated genes. By studying both muscular dystrophy (LGMD) and a better understand- disease pathology and investigating potential therapies, ing of how muscle degenerates in many of the different we hope to make a positive difference in the lives of dystrophies.
    [Show full text]
  • Analysis of the Dystrophin Interactome
    Analysis of the dystrophin interactome Dissertation In fulfillment of the requirements for the degree “Doctor rerum naturalium (Dr. rer. nat.)” integrated in the International Graduate School for Myology MyoGrad in the Department for Biology, Chemistry and Pharmacy at the Freie Universität Berlin in Cotutelle Agreement with the Ecole Doctorale 515 “Complexité du Vivant” at the Université Pierre et Marie Curie Paris Submitted by Matthew Thorley born in Scunthorpe, United Kingdom Berlin, 2016 Supervisor: Simone Spuler Second examiner: Sigmar Stricker Date of defense: 7th December 2016 Dedicated to My mother, Joy Thorley My father, David Thorley My sister, Alexandra Thorley My fiancée, Vera Sakhno-Cortesi Acknowledgements First and foremost, I would like to thank my supervisors William Duddy and Stephanie Duguez who gave me this research opportunity. Through their combined knowledge of computational and practical expertise within the field and constant availability for any and all assistance I required, have made the research possible. Their overarching support, approachability and upbeat nature throughout, while granting me freedom have made this year project very enjoyable. The additional guidance and supported offered by Matthias Selbach and his team whenever required along with a constant welcoming invitation within their lab has been greatly appreciated. I thank MyoGrad for the collaboration established between UPMC and Freie University, creating the collaboration within this research project possible, and offering research experience in both the Institute of Myology in Paris and the Max Delbruck Centre in Berlin. Vital to this process have been Gisele Bonne, Heike Pascal, Lidia Dolle and Susanne Wissler who have aided in the often complex processes that I am still not sure I fully understand.
    [Show full text]